AI-powered search

Featured Poster: Combining the 31-Gene Expression Profile Test for Cutaneous Melanoma with the American Joint Committee on Cancer Staging Identifies the Highest-Risk Patients with Stage I-II Disease

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Hyams and colleagues explore use of the 31-GEP test to stratify risks in cutaneous melanoma

By Dermsquared Editorial Team | June 16, 2023

Click here to view poster PDF

Although stage I-II melanomas are usually considered low risk, the majority of melanoma-associated deaths occur in patients diagnosed with these malignancies given the absolute number of cases and limitations of traditional staging systems.

The 31-Gene Expression Profile (31-GEP) test is a prognostic assay that measures the level of expression of 31 genes in a melanoma to further stratify risk of recurrence, metastasis, and mortality. This poster presents data from a large (N=6301), unselected cohort from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program who were 31-GEP tested and had a negative sentinel lymph node biopsy.

Within this cohort, patients with a Class 1A result had a 97.9% 5-year melanoma-specific survival (MSS) while those with a Class 1B/2A or Class 2B result had a 95.7% and 85.8% 5-year MSS, respectively.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved